Serum chemistry

DIAGNOSTIC_TEST3 trials

Sponsors

GWT-TUD GmbH, Kamari Pharma Ltd

Conditions

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Pachyonychia CongenitaPunctate Palmoplantar Keratoderma Type 1

Phase 1

Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases

CompletedNCT05435638

Kamari Pharma LtdPachyonychia Congenita, Punctate Palmoplantar Keratoderma Type 1

Start: 2022-07-17End: 2024-09-05Updated: 2025-01-07

Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC

CompletedNCT05956314

Kamari Pharma LtdPachyonychia Congenita, Punctate Palmoplantar Keratoderma Type 1

Start: 2023-03-06End: 2024-11-07Updated: 2025-01-15

Phase 2

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

TerminatedNCT02992860

GWT-TUD GmbHAcute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)

Start: 2016-07-31End: 2018-10-31Updated: 2018-10-25